tbuckley/cabot-search huggingface dataset:
Commentary: Health Effects of Air Pollution: Some Historical Notes
Authors: James L. Whittenberger
Journal: Environmental Health Perspectives (1989)

As I understand the objectives of this symposium, they are at least 2-fold: to describe some of the advances in the environmental health sciences in the past 40 years, and to acknowledge some of the roles of the Institute of En? vironmental Medicine in these scientific advances. This is a pleasant task and the occasion for a happy anniver? sary celebration. In my comments on air pollution, I expect to emphasize what is known to all of you?that environmental health sciences differ significantly from other health sciences in the extent to which they are intertwined with important public policy issues; in fact, the directions and progress of environmental health science research are often driven by public policy concerns and needs. The history of the Environmental Medicine Institute and the career of Nor?
196 COPEPTIN AS BIOMARKER OF SYSTEMIC HEMODYNAMIC DERANGEMENTS IN TAA CIRRHOTIC RATS
Authors: M. Coenraad, L. Verbeke, W. Laleman, F. Nevens, B. van Hoek, W. van Duijn, J. van der Reijden, H. Verspaget
Journal: Journal of Hepatology (2013)
Safe technique to treat occlusion of metallic endoscopic ultrasound-guided hepaticogastrostomy stent using a novel basket catheter (with video)
Authors: Takeshi Ogura, Akira Imoto, Daisuke Masuda, Rieko Kamiyama, Saori Onda, Kazuhide Higuchi
Journal: Endoscopy (2014)

Generally, to clean biliary metallic stents occluded by debris or food impaction, a balloon endoscopic retrograde cholangiopancreatography (ERCP) catheter has been widely used. Recently, a novel basket catheter has become available for removal of biliary or pancreatic stones (Reforma; Piolax Medical Devices Inc., Kanagawa, Japan) ([Fig. 1]) [1]. This device may have clinical relevance not just for stone removal, but also for cleaning of biliary metallic stents.
ABSOLUTE DISCHARGE LEVEL OR RELATIVE REDUCTION IN NT-PROBNP DURING HOSPITALISATION FOR ACUTE DECOMPENSATED HEART FAILURE AS A TARGET TO REDUCE 6-MONTH MORTALITY?
Authors: Susan Stienen, Khibar Salah, Luc Eurlings, Paulo Bettencourt, Marco Metra, Antoni Bayes-Genis, Luca Bettari, Jan Tijssen, Yigal Pinto, Wouter Kok
Journal: Journal of the American College of Cardiology (2015)
Vertebral Augmentation for Compression Fractures Caused by Malignant Disease
Authors: Rahul Rastogi, Trusharth Patel, Robert A. Swarm
Journal: Journal of the National Comprehensive Cancer Network (2010)

Vertebral compression fractures are common in malignant disease and frequently cause severe back pain. However, management of that pain with conventional medical, radiotherapy, or surgical modalities is often inadequate. Vertebral augmentation techniques, such as vertebroplasty and kyphoplasty, are minimally invasive techniques in which methylmethacrylate bone cement is percutaneously injected into compressed vertebral bodies. Vertebral augmentation often improves mechanical stability of compressed vertebrae, provides pain relief, and may prevent progression of vertebral collapse. Kyphoplasty may provide increased chance for vertebral body height restoration, but the clinical importance of slight change in vertebral body height is unclear. Vertebral augmentation can be used in conjunction with other treatment modalities, and associated pain relief may improve patient tolerance of needed antitumor therapies, such as radiation therapy. Vertebral augmentation is generally very well tolerated, and complications associated with bone cement extravasation beyond the vertebral body have rarely been reported. Because it often provides good to excellent relief of otherwise intractable pain and is generally well tolerated, vertebral augmentation is becoming a first-line agent for management of painful vertebral compression fractures, especially in the setting of malignant disease.
P356Dynamic nature of the methylation landscape of the heart
Authors: CM Greco, P Kunderfranco, P Carullo, R Papait, G Condorelli
Journal: Cardiovascular Research (2014)

Cardiac hypertrophy is associated with significant transcriptional changes characterized by the re- expression of fetal genes. Epigenetic mechanisms play a key role in defining the gene expression profile without modifying the actual DNA sequence. Recently, DNA methylation has been found to play a role in gene transcription regulation during heart failure, indicating that DNA methylation in the heart is a dynamic process. DNA methylation has been considered to be a stable modification that could only be removed by passive mechanisms during DNA replication. However, an active DNA de-methylation mechanism involving the hydroxylation of 5-methylcytosine (5-mC) to 5-hmC has emerged. Given the post-mitotic nature of cardiomyocytes, active de-methylation is likely to be involved in the dynamicity of the cardiac methylome. Nevertheless, the presence and possible function of 5-hmC in the heart has not been investigated yet. Therefore, we analyzed the genome-wide transcription and methylation/hydroxymethylation status of cardiomyocytes isolated from embryonic, neonatal, adult and hypertrophic (1 week pressure-overloaded) mouse heart with RNA, MeDIP and hMeDIP (5-mC/5-hmC DNA immunoprecipitation) high-throughput sequencings. We found that genomic regions enriched in 5-hmC were profoundly dynamic: in particular, adult cardiomyocytes were significantly enriched in 5-hmC at gene bodies, and hypertrophy was associated with a shift of this mark to intergenic regions and repetitive elements, recapitulating the landscape found in embryonic cardiomyocytes. We then assessed if there was a relationship between 5-hmC and gene transcription, as previously described for neurons. We found that the presence of 5-hmC at both promoter regions and gene bodies was associated with high levels of transcription. Moreover, integrative analysis of previously generated ChIP-seq data revealed a genome-wide strong co-localization of 5-hmC with active histone marks. Gene ontology analysis of genes harboring 5-hmC uncovered distinct gene sets for biological processes, molecular function and KEGG signature in embryonic, neonatal, adult and hypertrophic cardiomyocytes. Finally, differential analysis during the hypertrophic response revealed a strong enrichment of 5-hmC on a set of repetitive elements, which were also characterized by loss of H3K9me3, and contained a predicted binding site for cardiac specific transcription factors. Our study offers the first comprehensive analysis of 5-hmC in cardiomyocytes, and provides evidence that this epigenetic mark plays an important role in the heart under normal and stressed conditions.
Preferential Transduction of Human Hepatocytes with Lentiviral Vectors Pseudotyped by Sendai Virus F Protein
Authors: Claudia M. Kowolik, Jiing-Kuan Yee
Journal: Molecular Therapy (2002)

One of the major challenges facing gene therapy is the development of vectors targeting specific cell types. Restricting gene delivery to the relevant cell type leads to reduced T-cell responses to transgene products and prolonged gene expression. In this study, we demonstrate that vectors derived from human immunodeficiency virus (HIV) can be pseudotyped with Sendai virus fusion protein F. Such vectors transduced human hepatoma cells and primary human hepatocytes efficiently, but not non-liver cells. Several different approaches were also taken to significantly increase the titer of the pseudotyped vector. These studies may facilitate HIV vector-mediated gene delivery into liver in vivo.
Abstract 4508: Oxidative protein modifications in serous epithelia ovarian cancer tissues
Authors: Sharifeh Mehrabi, Yupha Vatcharapirjon, Tesfamariam Mehreteab, Gregory Adams, Felix O. Aikhionbare
Journal: Cancer Research (2012)

Abstract Despite advances in the surgical and chemotherapeutic management of ovarian cancer over the last decade, survival rates remain low, largely due to late diagnosis. Up to now very few candidate biomarkers have been investigated for early detection of ovarian cancer. The implication of ROS in female reproductive system and ovarian cancer are evidenced. Enzymatic antioxidants neutralize excessive ROS in cells. Under special condition, the cellular antioxidants are depleted. The ultimate aim of this study is to identify a biomarker for early detection of ovarian cancer. In this study 155 snap-freeze primary serous epithelial ovarian tissues including, normal, normal surrounding, cystadenoma, borderline and carcinoma with age range of 65±12,(55% Caucasian 45% Africa American), were analyzed. The objectives are: (a) to evaluate the protein expression profiles using two dimension gel electrophoresis (2-D SDS-PAGE) and LC/MS technology, (b) to identify and evaluate the level of oxidative modified protein, using derivatisation of protein carbonyl group with 2,4-dinitrophenylhyrdozine(DNPH) assay and western blot technique. Our results showed that the index of carbonyl protein /total protein increased by onset and progression of the serous ovarian malignancy. The elevation of oxidized protein among African American was 40 % higher than Caucasian in advanced stages of diseases. SDS-PAGE profiles showed a distinct protein pattern among cancerous and non-cancerous tissues. LC/MS analysis for elucidation of molecular changes of selected proteins bands is in progress. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4508. doi:1538-7445.AM2012-4508
ALTERATIONS IN URINE TGF-BETA MRNA IN RELATION TO ACUTE DECOMPENSATED HEART FAILURE: AN INDICATOR OF PERMANENT KIDNEY INJURY?
Authors: Parta Hatamizadeh, Todd Koelling, Mahboob Chowdhury, Judith Grossi, Su Q. Wang, Roger C. Wiggins
Journal: Journal of the American College of Cardiology (2015)
Care home resident challenges PCT's right to hive off services to a social enterprise without a proper tendering process
Authors: C. Dyer
Journal: BMJ (2012)

<h3>Introduction</h3> The global incidence of HCC is rising and it is the third most common cause of cancer-related death worldwide. Surveillance of at risk patients has been recommended by expert guidelines to detect early cancers that are amenable to curative treatments. AASLD has recommended HCC surveillance for non-cirrhotic HBV-positive Asian males over 40 and females over 50yrs of age. However, the evidence to support this recommendation is limited and is derived from studies conducted in Asia. Results from such studies may not be applicable in the West, due to differences in environmental risk factors and availability of HBV treatment. Implementation of such a recommendation would place a burden on healthcare resources, and may not be justified if the risk for HCC is substantially lower than previous estimates in this population. <h3>Methods</h3> A retrospective study was carried out of all Asian patients undergoing follow up for HBV infection from 1990 to 2012. Patients were classified as cirrhotic or non-cirrhotic according to clinical, biochemical, radiological and histological results. Follow-up was until September 2012, and was censored at time of death, development of cirrhosis or loss to follow-up. <h3>Results</h3> Among 316 identified Asian patients with HBV, 73 non-cirrhotic patients fulfilled the proposed AASLD surveillance criteria, either at time of initial referral or during the period of follow-up. The median at-risk follow up period (as defined by AASLD guidelines for non-cirrhotic Asians) was 57 months (range: 0–354 months). HCC was diagnosed in one non-cirrhotic patient after 77 months of follow up (male, 60yrs), two patients became cirrhotic after 49 and 89 months (male, age 46 and 55yrs) and no deaths occurred. The overall incidence of HCC in the non-cirrhotic cohort meeting the AASLD surveillance criteria was 1 per 429.5 patient-years of follow-up (0.23% per patient-year). <h3>Conclusion</h3> The incidence of HCC in Asian patients with non-cirrhotic HBV is low in our cohort. This low incidence challenges the rationale for surveillance in this group of patients. More studies are needed to assess the benefit of such approach. <h3>Disclosure of Interest</h3> None Declared.
AB1380 The impact of osteoarthritis on the functioning of individuals: A statistical validation of the brief ICF core set for osteoarthritis based on a large international sample of patients with osteoarthritis
Authors: R. Escorpizo, C. Oberhauser, A. Boonen, G. Stucki, A. Cieza
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The International Classification of Functioning, Disability and Health (ICF)<sup>1</sup> is a reference framework to describe the impact of health conditions on functioning and disability. A Comprehensive and Brief ICF Core Set for osteoarthritis (OA) has been developed<sup>2</sup> and must be statistically validated. <h3>Objectives</h3> Our specific aims were (1) to identify ICF categories that best explain patients’ functioning, (2) to determine the content validity of the Brief ICF Core Set, and (3) to propose a statistically-validated version. <h3>Methods</h3> Psychometric study using Group Lasso regression on data from a convenience sample of 879 OA patients from 20 countries. The subscale on general health of the SF-36 was used as dependent variable and all ICF categories of the Comprehensive ICF Core Set for OA and some socio-demographics and disease-specific characteristics as independent variables. The most relevant ICF categories were identified as those showing a significant effect based on the pointwise 90% confidence intervals resulting from 1000 bootstrap trials. <h3>Results</h3> Based on our results, there were 15 ICF categories included in the statistically-validated version of the Brief ICF Core Set for OA: five body functions (sensation of pain, mobility of joint, muscle power, energy and drive, and emotional functions), three body structures (structure of upper extremity, structure of lower extremity, and additional musculoskeletal structures related to movement), three activities and participation (hand and arm use, walking, and dressing), and four environmental factors (products and technology for personal use in daily living, immediate family, health services, systems and policies, and societal attitudes). Twelve of the original 13 Brief ICF Core Set categories were confirmed, and three additional ICF categories were identified. <h3>Conclusions</h3> Our findings reassure the validity of the Brief ICF Core Set for OA. The statistically validated Core Set (12 categories out of 13) with the additional three statistically-derived ICF categories will likely perform better with regard to discrimination and sensitivity to change in studies and trials, and should be further explored in the future. <h3>References</h3> World Health Organization. International Classification of Functioning, Disability, and Health. WHO: Geneva, 2001. Dreinhöfer K, Stucki G, Ewert T, et al. ICF Core Sets for osteoarthritis. J Rehabil Med. 2004;(44 Suppl):75-80. <h3>Disclosure of Interest</h3> None Declared
A4.12 Vitamin D in patients with atherosclerosis - a link between atherosclerosis and bone mass?
Authors: P Oliveira Santos, D Carmona-Fernandes, S Barreira, A Nicolau Fernandes, L Mendes Pedro, A Castro, H Canhão, J E Fonseca, M J Santos
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> Vitamin D is thought to protect the cardiovascular system, although its role is not completely clear. The beneficial effect may occur by vascular calcification inhibition through blockage of both inflammatory cytokines and adhesion molecules. Moreover, calcitriol is a renin negative regulator, interfering in renin-angiotensin-aldosterone system (RAAS) and limiting the production of angiotensin II, an inflammatory and atherogenic cytokine implicated in the development of atheromatous plaques. Epidemiological studies showed an association between osteoporosis and atherosclerosis, which suggests the existence of common underlying mechanisms. We aimed to analyse the relationship between vitamin D serum levels, the severity of atherosclerosis and bone mineral density (BMD) and to explore the importance of both arterial blood pressure and inflammation as mediators of the relationship between vitamin D and atherogenesis. Patients who underwent carotid endarterectomy in the Vascular Surgery Department of Hospital de Santa Maria were included. A structured clinical protocol was applied to those who agreed to participate and many important personal data (age; gender; traditional cardiovascular risk factors; date of the surgery; personal and family history of bone fractures, osteoporosis and other relevant diseases; patient's medication) were recorded, as well as many variables, like calcidiol, degree of carotid stenosis, BMD (obtained by dual-energy X-ray absorptiometry), mean arterial pressure (MAP) and C-reactive protein (CRP). The correlations between calcidiol and both degree of stenosis and BMD were not statistically significant. There were no cross-sectional association between MAP and serum calcidiol or the percentage of stenosis and the latter and BMD levels were not significantly different in patients with and without sufficient/adequate vitamin D levels. Despite the existing evidence that vitamin D has a protective role in cardiovascular system through many pathways, our results do not substantiate that premise. Mean arterial blood pressure and C-reactive protein didn't correlate with both vitamin D and percentage of stenosis. It is important to have in mind that this study had some limitations (like sample dimension, the cross-sectional design and the exclusion of many confounders). Nevertheless we highlight the importance of vitamin D in cardiovascular system, encouraging the reflection about points that could strengthen the results of future projects.
Abstract 2615: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models
Authors: Rudi Bao, Dagong Wang, Hui Qu, Ling Yin, Guang-Xin Xu, Steven DellaRocca, Mylissa Borek, Ruzanna Atoyan, Jeffrey Forrester, Maria Samson, Jing Wang, Hai-Xaio Zhai, Mendy Chan, Cheng-Jung Lai, Xiong Cai, Changgeng Qian
Journal: Cancer Research (2011)

Abstract Recent evidence indicates that PI3K-Akt-mTOR signaling plays a crucial role in the development and progression of hematologic cancers. Therefore, inhibition of this pathway using isotype-selective or pan-PI3K inhibitors has recently been investigated extensively in hematologic malignancies. However, compensatory/feedback mechanisms in cancer cells may present a major challenge for these PI3K inhibitors. On the other hand, HDAC inhibitors, such as vorinostat and romidepsin, have been approved as a monotherapy for CTCL. Their efficacy as single agent or in combination with other approved therapeutics is being evaluated in multiple clinical trials for other types of hematologic cancers, including DLBCL, Hodgkin lymphoma, AML, ALL, CLL, and multiple myeloma. Based on the observation that synergic effects can be achieved by inhibition of both HDAC and PI3K in cancer cells as reported previously, we developed small-molecule compounds that are able to simultaneously inhibit both PI3K and HDAC. One of the lead compounds exhibits potent inhibition of all PI3K class I subtypes as well as HDAC. In cell growth inhibition assays, this compound displays potent activity in hematologic cancer cell lines, including leukemia, lymphoma, and myeloma. Besides PI3K-Akt-mTOR pathway suppression, this compound is able to up-regulate tumor suppressors p53 and p21 and simultaneously inhibit compensatory Ras-Raf-MEK signaling in cancer cells via epigenetic modifications by HDAC inhibition. In vivo experiments demonstrate this compound is orally bio-available with a long half-life in tumor tissues from xenograft models. Efficacy studies demonstrate this compound is able to inhibit tumor growth or induce tumor regression in animals implanted with various hematologic cancer cell lines. Furthermore, this compound induces apoptosis and inhibits cancer cell proliferation in these tumor xenografts. Favorable safety profile has been observed in early preclinical studies. Based on these results, this compound warrants further investigation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2615. doi:10.1158/1538-7445.AM2011-2615
Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience
Authors: Phil A Hart, Michael J Levy, Thomas C Smyrk, Naoki Takahashi, Barham K Abu Dayyeh, Jonathan E Clain, Ferga C Gleeson, Randall K Pearson, Bret T Petersen, Mark D Topazian, Santhi S Vege, Lizhi Zhang, Suresh T Chari
Journal: Gut (2015)

Idiopathic duct-centric chronic pancreatitis (IDCP), also known as type 2 autoimmune pancreatitis (AIP), is an uncommon subtype of AIP. International Consensus Diagnostic Criteria for IDCP propose that the diagnosis requires pancreatic histology and/or concurrent IBD. We examined our experience with IDCP (type 2 AIP) to assess the appropriateness of these criteria, and identify unique characteristics in patients presenting with acute pancreatitis.We reviewed the Mayo Clinic AIP database through May 2014 to identify subjects with either definitive (n=31) or probable (n=12) IDCP. We compared demographic and clinical factors based on strength of diagnostic confidence (definitive versus probable), presence of IBD, and acute pancreatitis as the presenting manifestation. Relapse-free survival was determined using the Kaplan-Meier method.The clinical profiles were similar irrespective of the diagnostic criteria fulfilled. Common clinical presentations included acute pancreatitis (n=25, 58.1%, 12 of whom (27.9%) had recurrent pancreatitis) and pancreatic mass/obstructive jaundice (n=15, 34.9%). The cumulative relapse rate was 10.6% at 3 years (median follow-up 2.9 years). Relapse-free survival was similar for the different diagnostic categories, but was decreased in those initially presenting with acute pancreatitis (p=0.047) or treated with steroids (vs surgery, p=0.049).The current diagnostic classification of probable IDCP and the inclusion of IBD as a supportive criterion appear valid, because patients have similar clinical profiles and disease-related outcomes to those with definitive IDCP. Concurrent IBD, especially in young patients, may suggest when IDCP is the underlying cause of recurrent acute pancreatitis, but additional studies are needed for validation.